Chinese Journal of Cancer Research最新文献

{"title":"Immune decoding from a multi-omics perspective: Redefining pancreatic cancer tumor microenvironment.","authors":"Enkui Zhang, Yinmo Yang","doi":"10.21147/j.issn.1000-9604.2026.03.08","DOIUrl":"10.21147/j.issn.1000-9604.2026.03.08","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 3","pages":"311-314"},"PeriodicalIF":6.7,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148410589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breakthroughs of chimeric antigen receptor T-cell therapy in hematological malignancies: From <i>ex vivo</i> to <i>in vivo</i>.","authors":"Xuying Pei, Yuxuan Du, Meng Lyu, Xiaojun Huang","doi":"10.21147/j.issn.1000-9604.2026.03.02","DOIUrl":"10.21147/j.issn.1000-9604.2026.03.02","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 3","pages":"291-294"},"PeriodicalIF":6.7,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148410640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric cancer surgery in the era of neoadjuvant immunotherapy.","authors":"Jiafu Ji, Ke Ji, Hao Su","doi":"10.21147/j.issn.1000-9604.2026.03.05","DOIUrl":"10.21147/j.issn.1000-9604.2026.03.05","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 3","pages":"301-303"},"PeriodicalIF":6.7,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148410628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in diagnosis and treatments of acute leukemia.","authors":"Lijuan Hu, Yi Xia, Xiaodong Mo, Xiaojun Huang","doi":"10.21147/j.issn.1000-9604.2026.03.09","DOIUrl":"10.21147/j.issn.1000-9604.2026.03.09","url":null,"abstract":"<p><p>Acute leukemia remains a life-threatening hematologic malignancy with historically poor outcomes in relapsed/refractory and elderly patients. Over the past decade, measurable residual disease (MRD) has evolved from a prognostic indicator to a core determinant of risk stratification and clinical decision-making, driving a paradigm shift toward precision medicine. Technological innovations-including leukemia stem cell (LSC)-directed MRD detection, single-cell sequencing, and personalized digital polymerase chain reaction (PCR)-have markedly improved the sensitivity and specificity of MRD monitoring, enabling the early identification of patients at ultrahigh risk of relapse. Concurrently, targeted therapy has moved from salvage to frontline standard care; the use of FLT3, IDH1/2, and BCR-ABL1 inhibitors combined with chemotherapy or immunotherapy has significantly prolonged remission, improved MRD negativity rates, and redefined prognostic stratification. Novel cellular therapies, particularly CD19/CD22-targeted chimeric antigen receptor T (CAR-T) and bispecific T-cell engagers, have revolutionized the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation (allo-HSCT), optimized by the \"Beijing Protocol\" for haploidentical donors, remains the cornerstone of curative intent. Low-toxicity regimens, such as venetoclax plus hypomethylating agents, have transformed care for elderly or unfit patients, shifting goals from palliation to long-term survival. Despite these advances, challenges, including antigen escape, CAR-T-cell persistence, graft-versus-host disease, and treatment accessibility, persist. This commentary summarizes landmark progress in MRD-guided precision stratification, targeted therapy, cellular immunotherapy, and allo-HSCT; discusses unresolved clinical bottlenecks; and proposes future directions centered on dynamic MRD monitoring, personalized targeted-immunotherapy combinations, and risk-adapted transplantation strategies to further improve cure rates and long-term survival across all acute leukemia subtypes.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 3","pages":"315-328"},"PeriodicalIF":6.7,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343187/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148410571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is sentinel node navigation surgery feasible after non-curative endoscopic resection in patients with early gastric cancer?","authors":"Bang Wool Eom, Woo Jun Ahn, Hong Man Yoon, Young Woo Kim, Keun Won Ryu","doi":"10.21147/j.issn.1000-9604.2026.03.12","DOIUrl":"10.21147/j.issn.1000-9604.2026.03.12","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 3","pages":"340-342"},"PeriodicalIF":6.7,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148410569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updates of CSCO guidelines for diagnosis and treatment of lymphoma: 2026 edition.","authors":"Weiping Liu, Donglu Zhao, Jun Ma, Jun Zhu, Yuqin Song","doi":"10.21147/j.issn.1000-9604.2026.03.11","DOIUrl":"10.21147/j.issn.1000-9604.2026.03.11","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 3","pages":"336-339"},"PeriodicalIF":6.7,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343201/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148410680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Turmoil and breakthroughs: Highlights and growing pains in breast cancer therapy 2025<b>-</b>2026.","authors":"Mingxia Jiang, Binghe Xu","doi":"10.21147/j.issn.1000-9604.2026.03.03","DOIUrl":"10.21147/j.issn.1000-9604.2026.03.03","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 3","pages":"295-297"},"PeriodicalIF":6.7,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148410645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing evolution of metastatic prostate cancer: From hormone-sensitive to castration-resistant disease.","authors":"Shengpan Wu, Xu Zhang","doi":"10.21147/j.issn.1000-9604.2026.03.04","DOIUrl":"10.21147/j.issn.1000-9604.2026.03.04","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 3","pages":"298-300"},"PeriodicalIF":6.7,"publicationDate":"2026-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13343173/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148410574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting nature of stage III non-small cell lung cancer: Anatomically defined, biologically systemic.","authors":"Guoyin Li, Xi Zhang, Xiaolu Fu, Xuewen Liu, Zewen Song","doi":"10.21147/j.issn.1000-9604.2026.02.08","DOIUrl":"10.21147/j.issn.1000-9604.2026.02.08","url":null,"abstract":"<p><p>Stage III non-small cell lung cancer (NSCLC) is traditionally viewed as a locally advanced disease based on anatomic imaging. It is increasingly recognized as a systemic illness with localized manifestations, as evidenced by high rates of distant recurrence despite aggressive local therapy. Recent landmark trials (e.g., ADAURA, ALINA, PACIFIC, and KEYNOTE 671) have demonstrated that prolonged systemic treatment, including adjuvant targeted therapy in oncogene-driven NSCLC and consolidation immune checkpoint inhibition after chemoradiotherapy, significantly improves survival outcomes. In contrast, intensifying local therapy alone has exhibited limited benefit or even potential harm. Supporting this shift, detection of circulating tumor DNA and circulating tumor cells indicates the presence of micrometastatic disease at the time of diagnosis. We propose an integrated \"sandwich\" therapeutic framework encompassing three sequential phases: 1) induction with biomarker-guided systemic therapy (e.g., targeted agents or chemoimmunotherapy) to control micrometastases; 2) local consolidation with surgery or radiotherapy tailored to the post-induction tumor extent; and 3) systemic consolidation with prolonged maintenance therapy to eradicate residual disease. This approach underscores the necessity of treating stage III NSCLC as a systemic disease from the outset, integrating prolonged, biomarker-directed systemic strategies within a multimodal curative-intent framework to address both the local and systemic components of the disease.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 2","pages":"209-233"},"PeriodicalIF":6.7,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13171411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From spatial maps to therapeutic targets: Next challenge for artificial intelligence in cancer spatial omics.","authors":"Hui Xu, Yuyuan Zhang, Yuqing Ren, Peng Luo, Haidong Zhu","doi":"10.21147/j.issn.1000-9604.2026.02.06","DOIUrl":"10.21147/j.issn.1000-9604.2026.02.06","url":null,"abstract":"","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"38 2","pages":"200-203"},"PeriodicalIF":6.7,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13171415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}